Welcome to the INA-RESPOND public website.
Current and expanding infectious disease profile in Indonesia warrants a sense of urgency and mandates that research be a priority to guide the management and prevention of disease to reduce morbidity and mortality. The purpose of Indonesia Research Partnership on Infectious Diseases (INA-RESPOND) is to bring together clinical and academic medical institutions to develop a robust collaborative infectious disease research network.
About INA-RESPOND: The Indonesian Research Partnership on Infectious Disease (INA-RESPOND) stands at the forefront of infectious disease research. Our esteemed network comprises professionals driven to make meaningful contributions to the global understanding of communicable diseases. We promote innovative solutions and approaches in the battle against infectious diseases by forging cooperation with premier universities and researchers
By: Aly Diana Photovoice, a participatory action research methodology, represents a significant evolution in how data is collected, analyzed, and utilized in various fields, including healthcare. This approach empowers participants to capture images reflecting their personal experiences, insights, and environments, offering a rich visual narrative that complements traditional research methods. The essence of Photovoice lies
By: Putri Permata Sari, Titin Dani Martiwi, Adhella Menur Brief history of polio, outbreaks, and towards a polio-free world When we hear “polio” or “poliomyelitis,” we might imagine a child with a small and floppy, one-sided leg, emblematic of the spectrum of disabilities caused by poliovirus infection that has plagued humanity since ancient times. Evidence
By: Gustiani Salim Enhancing Laboratory Skills and Capacity in TB Biomarker Research For the first time, RePORT International held a Junior Investigator Training program aimed at enhancing the capacity and laboratory skills of staff from RePORT International member countries. This training provides participants the opportunity to learn not only from expert scientists directly but also
Beloved child, wife, mother, friend | NIA KURNIATI 1965 – 2024 Dr. Nia Kurniati’s passing on January 17, 2024, marks a profound loss for the medical community, especially our INA-RESPOND network family. Her dedication to improving pediatric HIV care, her contributions to research, and her role as a mentor and educator leave a lasting legacy
To collect standardized baseline and longitudinal data describing the course of HIV disease in antiretroviral-naive and treatment-experienced individuals to inform policy.
Implementing a Combination of Clinical Parameters (Rapid Diagnostic Tests, Biomarkers and Standard of Care Procedures) for the Etiology Diagnosis of Pneumonia in Paediatric Patients to Improve Clinical Management in Indonesia
To identify COVID-19 and other respiratory infectious disease cases from hospitalized suspected COVID-19 patients.
to compare the virological efficacy of the three regimens in the intention to treat (ITT) population. Virological efficacy is defined as the proportion of participants with plasma HIV RNA (pVL) <50 copies/mL at 48 weeks.
Among participants testing positive for SARS-CoV-2: Estimate the rate of hospitalization or death during the 28 day follow-up period. Identify risk factors for hospitalization or death.
Primary Objective: The primary endpoint of this trial in hospitalized patients is an ordinal outcome based on the patient’s clinical status on Day 7. It includes seven mutually exclusive categories capturing the range of organ dysfunction that may be associated with the progression of COVID-19, such as respiratory dysfunction and coagulation-related complications.
To characterize immunogenicity (by measurement of anti-S Ab) of available COVID-19 vaccine regimens in people who received an initial vaccine or booster regimen, in each of the countries at 2 months after completion of the initial full vaccine regimen or booster vaccine regimen.
To identify the etiology of acute febrile illness cases and evaluate clinical manifestations and outcomes.
To determine the causes of community-acquired sepsis and severe sepsis in adults and pediatrics across Southeast Asia.
To estimate the proportion of MDR TB amongst treatment naïve new treatment naïve and previously treated cases.
